The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

ABSTRACT - 600267 The disclosure relates to an agent consisting of theobromine and an antihistamine as a combined preparation for use in a therapy of cough, wherein the agent is manufactured for administration by an oral route, wherein the antihistamine is selected from diphenhydramine, loratadine, desloratadine, alimemazine, dimenhydrinate, doxylamine, meclizine, quetiapine, fexofenadine, pheniramine, cetirizine, promethazine, clemastine, chlorpheniramine, dexchlorpheniramine, levocetirizine, h...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury.In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine bromphenirami...

FIELD: medicine. ^ SUBSTANCE: invention refers to medical products and concerns applications of a film for internal application containing triprolidine or its salt or hydrate as an active component of the remedy for awakening vigorous after sleeping. There is also disclosed method for treatment or prevention of sluggishness or somnolence in awakening after sleeping the method that makes it possible for an individual to wake up vigorous after sleeping and the method ensuring falling asleep of an ...

The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monens...

The present invention relates to methods for enhancing Hypoxia inducible factor- 1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monen...

A Process for the synthesis of (E) - 2 - [1 - (4 - methyl phenyl) -3- (1- pyrrolidinyl)-l- propenyl] pyridine (TRIPROLIDINE) by reacting 2-(l-pyrrolidino)ethyl triphenyl phosphonium bromide with 2-(p-toluoyl) pyridine in presence of aprotic solvent and a base isomeising in presence of acid catalyst.

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...